Liquid purification or separation – Casing divided by membrane into sections having inlet – Antithrombogenic membrane
Patent
1991-02-11
1993-10-19
Dawson, Robert A.
Liquid purification or separation
Casing divided by membrane into sections having inlet
Antithrombogenic membrane
2103218, 21050023, 21050024, 21050036, 422 44, 604 4, 604 5, B01D 6302
Patent
active
052542491
DESCRIPTION:
BRIEF SUMMARY
DESCRIPTION
1. Technical Field
The present invention relates to a new anti-thrombogenic blood treating system combining medical materials excellent in anti-thrombogenic property, with an artificial kidney of selectively permeable hollow yarn membranes excellent in anti-thrombogenic property, contamination resistance and solute permeability.
2. Background Arts
In recent years, hemocathartic therapy using extra corporeal circulation for a relatively long time such as CAVH is practiced, and many anti-thrombogenic materials have been being developed as medical materials used for it. However, still now, an anticoagulant such as heparin is administered to the whole body to make the blood non-coagulable for preventing the thrombogenesis. The administration of heparin, etc. to the whole body has a large disadvantage that the danger of bleeding becomes considerably high, and so, there is not yet any system which allows safe extracorporeal circulation.
Japanese Patent Laid-Open No. 85-22901 proposes the use of a copolymer with polyethylene oxide component as a hydrophilic high polymer. Japanese Patent Laid-Open No. 82-14358 discloses a heparinized hydrophilic copolymer containing vinyl chloride as a main component monomer, and Japanese Patent Laid-Open No. 83-5320 discloses a graft vinyl chloride copolymer containing a polyethylene oxide component of 5 or more in polymerization degree, as a medical anti-thrombogenic material.
However, these prior arts are insufficient as a practical anti-thrombogenic blood treating system for extracorporeal circulation, even though the anti-thrombogenic property of each material is greatly improved. Thus, the use of an anticoagulant such as heparin has been inevitable in practical extracorporeal circulation.
In view of the disadvantage of the above mentioned prior arts, the object of the present invention is to provide a safe anti-thrombogenic extracorporeal circulation system which allows extracorporeal circulation without using any anticoagulant such as heparin.
DISCLOSURE OF THE INVENTION
The present invention is an anti-thrombogenic blood treating system, comprising selectively permeable hollow yarn membranes containing a copolymer with polyethylene oxide component, and headers, catheters and circuits respectively covered on the blood contact surface with a heparinized hydrophilic copolymer containing vinyl chloride as a component monomer or a hydrophilic copolymer with polyethylene oxide component, in combination.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a general view showing the blood treating system of the present invention.
FIG. 2 is a sectional view showing the junction between a catheter tube and a connector.
FIG. 3 is a sectional view showing the header the inlet side.
The following numbers and letters, and their corresponding descriptions, have been selected for ease of understanding of the invention herein.
______________________________________ 1, 1': catheter tube
2, 2': threaded catheter connector
3: connector
4, 4': cap for fixing the threaded connector
5, 5': blood circuit
6, 6': blood collecting section
7, 7': connector
8: blood inlet port
8': blood outlet port
9: header on inlet side
10, 10': silicone packing
11: inside space
12, 12': sealing material
13: end face of hollow yarn membranes
14, 14': filtrate outlet
15: module case
16: hollow yarn
17: header on outlet side
18: transfusion circuit
a: inlet of blood circuit
b: outlet of blood circuit
c: junction face between catheter tube and
connector
d: hydrophilic copolymer covering layer
e: close contact portion between catheter
connector and circuit connector
f: covering film
g: space inside hollow yarn
______________________________________
BEST MODE FOR CARRYING OUT THE INVENTION
The selectively permeable hollow yarn membrane of the present invention must contain, at least as one component, a copolymer with polyethylene oxide component to give anti-thrombogenic property, preferably a copolymer consisting of a polymerizable monomer with a
REFERENCES:
patent: 3673612 (1972-07-01), Merrill et al.
patent: 3844989 (1974-10-01), Harumiya et al.
patent: 4269712 (1981-05-01), Hornby et al.
patent: 4424311 (1984-01-01), Nagaoka et al.
patent: 4425234 (1984-01-01), Reitz
patent: 4812269 (1989-03-01), Harttig et al.
patent: 4871357 (1989-10-01), Hsu et al.
patent: 4872867 (1989-10-01), Joh
patent: 4888109 (1989-12-01), Manohar
patent: 4906465 (1990-03-01), Chaikof et al.
patent: 4965112 (1990-10-01), Brinkman et al.
"Development of a New Antithrombogenic Continuous Ultrafiltration System", M. Arakawa et al, Artificial Organs, vol. 15, No. 3, 1991, pp. 171-179.
"Heparinized Polymers as Thromboresistant Biomaterials", J. E. Wilson, Polm.-Plast. Technol. Eng., 16(2), 1981, pp. 119-208.
Kunitomo Tetsunosuke
Tanaka Kazumi
Terada Ryozo
Dawson Robert A.
Kim Sun Uk
Miller Austin R.
Toray Industries Inc.
LandOfFree
Anti-thrombogenic blood treating system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-thrombogenic blood treating system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-thrombogenic blood treating system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1349489